Zymeworks Executive Changes: Mark Hollywood Promoted to COO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy ZYME?
Mark Hollywood has been promoted to Executive Vice President and COO with expanded responsibilities beyond his current leadership of Technology and Manufacturing Operations, Quality, and Alliance/Program Management. Dr. Sabeen Mekan has been promoted to Senior Vice President and Chief Medical Officer effective February 1, with overall responsibility for clinical development, regulatory affairs, pharmacovigilance/patient safety, and clinical operations. Dr. Jeff Smith, current CMO, will be retiring effective January 31, while continuing to provide services as an adviser for a transitional time period. Leone Patterson, Chief Financial and Business Officer and Daniel Dex, General Counsel, will both be departing from their roles at Zymeworks during the first quarter of 2026. The company has commenced a comprehensive search for a permanent CFO with the experience required to support the company's next phase of development. Galbraith has assumed the role of Acting CFO until a replacement is secured.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZYME?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZYME
Wall Street analysts forecast ZYME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYME is 35.55 USD with a low forecast of 30.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.020
Low
30.00
Averages
35.55
High
42.00
Current: 22.020
Low
30.00
Averages
35.55
High
42.00
About ZYME
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zymeworks (ZYME) 2026 Milestones Expected to Drive Long-Term Value with Promising ZW191 Data
- ZW191 Clinical Progress: Zymeworks' ZW191 shows a 64% overall response rate in phase 1 trials for advanced solid tumors, particularly among gynecological cancer patients receiving doses of 6.4 mg/kg or higher, indicating significant therapeutic potential that could drive long-term value for the company.
- Dose Optimization Initiated: The company has commenced dose optimization of ZW191 in ovarian cancer in the previous quarter, aiming to enhance efficacy and meet patient needs, thereby strengthening its competitive position in the market.
- Zanidatamab Milestones: Zymeworks is poised to receive substantial milestone payments related to its licensed program Zanidatamab, which is approved in the U.S. for HER2-positive biliary tract cancer, showcasing the company's robust potential in the biopharmaceutical sector.
- Strong Cash Reserves: As of December 31, 2025, Zymeworks held approximately $270.6 million in cash, providing ample funding for future R&D and market expansion, thereby enhancing its capacity for sustained growth in the industry.
See More
Zymeworks Appoints New Board Member and Executive Leadership Changes
- Board Enhancement: Brian Cherry appointed to the Board on January 12, 2026, brings over $25 billion in investment experience, aiming to enhance long-term shareholder value through optimized capital allocation and strategic acquisitions.
- Executive Promotions: Mark Hollywood promoted to Executive Vice President and Chief Operating Officer, expanding responsibilities to drive growth and operational efficiency in the company's next phase.
- Leadership Transitions: Dr. Sabeen Mekan will transition to Chief Medical Officer effective February 1, 2026, overseeing clinical development and regulatory affairs to ensure compliance and safety in drug development.
- New Vice Presidents: Zymeworks appointed five new Vice Presidents, underscoring the company's commitment to leadership development and enhancing the capabilities and experience of its management team through internal talent cultivation.
See More
Zymeworks Appoints New Directors and Executives to Strengthen Leadership Team
- Board Enhancement: Brian Cherry appointed to the Board on January 12, 2026, brings over $25 billion in investment experience, aiming to leverage his expertise in capital allocation and strategic acquisitions to support effective execution of the company's new strategy and enhance long-term shareholder value.
- Executive Promotions: Mark Hollywood promoted to Executive Vice President and Chief Operating Officer, overseeing technology, manufacturing operations, and quality management, expected to drive growth in the biotechnology sector through expanded responsibilities.
- Leadership Transition: Sabeen Mekan will transition to Chief Medical Officer effective February 1, 2026, responsible for clinical development and regulatory affairs, ensuring compliance and safety in drug development to enhance the company's market competitiveness.
- New Vice Presidents: Five new Vice Presidents appointed, underscoring the company's commitment to leadership development, which will enhance the team's expertise to better achieve strategic objectives and drive long-term growth.
See More
Zymeworks (ZYME) Reports Positive Phase 3 HERIZON-GEA-01 Results for Ziihera with Up to $440M in Milestone Payments
- Phase 3 Trial Results: Zymeworks presented positive results for Ziihera (zanidatamab-hrii) in the HERIZON-GEA-01 trial for HER2-positive gastroesophageal adenocarcinoma at ASCO GI, indicating strong potential as a first-line treatment.
- Milestone Revenue: The company stated that up to $440 million in milestone payments related to regulatory approvals of Ziihera in the U.S., Europe, Japan, and China could significantly enhance its financial position and market competitiveness.
- Cash Flow Outlook: As of December 31, 2025, Zymeworks holds approximately $270.6 million in cash, cash equivalents, and marketable securities, which, combined with anticipated regulatory milestone payments, is expected to provide cash runway beyond 2028.
- R&D Pipeline Progress: The company is conducting a global Phase 1 trial of ZW191 for solid tumors, with dose optimization underway, and further data from this study is expected to be presented at a major medical conference in 2026, bolstering its R&D capabilities.
See More
Zymeworks Reports Positive Phase 3 Results for Ziihera with Up to $440 Million in Potential Milestones
- Clinical Trial Success: Ziihera demonstrated significant improvement in progression-free survival in the HERIZON-GEA-01 Phase 3 trial for HER2-positive gastroesophageal adenocarcinoma, exceeding a four-month increase over the control group, which is expected to drive future regulatory approvals and market sales.
- Potential Revenue Growth: Zymeworks anticipates up to $440 million in regulatory milestone payments, with $250 million from the U.S. market, significantly enhancing the company's financial flexibility and long-term growth potential.
- Share Repurchase Program: The company announced a $125 million share repurchase plan in November 2025, having repurchased approximately $19 million worth of shares, aimed at enhancing shareholder value by reducing the share count while maintaining cash resources for operations and growth investments.
- Strong Financial Foundation: As of December 31, 2025, Zymeworks reported approximately $270.6 million in cash and cash equivalents, combined with anticipated regulatory milestone payments, expected to support operations beyond 2028, ensuring long-term sustainable growth.
See More
Zymeworks Reports Positive Phase 3 HERIZON-GEA-01 Results for Ziihera with Up to $440M in Milestone Payments
- Clinical Trial Success: Ziihera demonstrated significant improvement in progression-free survival in the HERIZON-GEA-01 Phase 3 trial for HER2-positive gastroesophageal adenocarcinoma, exceeding a four-month increase over the control group, which is expected to drive future regulatory approvals.
- Milestone Payment Potential: Zymeworks stands to earn up to $440 million in milestone payments from regulatory approvals of Ziihera, with $250 million potentially from the U.S. market, highlighting the company's strong growth potential in global markets.
- Share Repurchase Program: The company announced a $125 million share repurchase plan in November 2025, aimed at enhancing shareholder value by reducing share count while maintaining financial flexibility for future growth investments.
- Strong Financial Foundation: As of December 31, 2025, Zymeworks reported approximately $270.6 million in cash and cash equivalents, combined with anticipated milestone payments, expected to support operations beyond 2028, ensuring long-term financial stability.
See More
Zymeworks (ZYME) 2026 Milestones Expected to Drive Long-Term Value with Promising ZW191 Data
- ZW191 Clinical Progress: Zymeworks' ZW191 shows a 64% overall response rate in phase 1 trials for advanced solid tumors, particularly among gynecological cancer patients receiving doses of 6.4 mg/kg or higher, indicating significant therapeutic potential that could drive long-term value for the company.
- Dose Optimization Initiated: The company has commenced dose optimization of ZW191 in ovarian cancer in the previous quarter, aiming to enhance efficacy and meet patient needs, thereby strengthening its competitive position in the market.
- Zanidatamab Milestones: Zymeworks is poised to receive substantial milestone payments related to its licensed program Zanidatamab, which is approved in the U.S. for HER2-positive biliary tract cancer, showcasing the company's robust potential in the biopharmaceutical sector.
- Strong Cash Reserves: As of December 31, 2025, Zymeworks held approximately $270.6 million in cash, providing ample funding for future R&D and market expansion, thereby enhancing its capacity for sustained growth in the industry.
See More
Zymeworks Appoints New Board Member and Executive Leadership Changes
- Board Enhancement: Brian Cherry appointed to the Board on January 12, 2026, brings over $25 billion in investment experience, aiming to enhance long-term shareholder value through optimized capital allocation and strategic acquisitions.
- Executive Promotions: Mark Hollywood promoted to Executive Vice President and Chief Operating Officer, expanding responsibilities to drive growth and operational efficiency in the company's next phase.
- Leadership Transitions: Dr. Sabeen Mekan will transition to Chief Medical Officer effective February 1, 2026, overseeing clinical development and regulatory affairs to ensure compliance and safety in drug development.
- New Vice Presidents: Zymeworks appointed five new Vice Presidents, underscoring the company's commitment to leadership development and enhancing the capabilities and experience of its management team through internal talent cultivation.
See More
Zymeworks Appoints New Directors and Executives to Strengthen Leadership Team
- Board Enhancement: Brian Cherry appointed to the Board on January 12, 2026, brings over $25 billion in investment experience, aiming to leverage his expertise in capital allocation and strategic acquisitions to support effective execution of the company's new strategy and enhance long-term shareholder value.
- Executive Promotions: Mark Hollywood promoted to Executive Vice President and Chief Operating Officer, overseeing technology, manufacturing operations, and quality management, expected to drive growth in the biotechnology sector through expanded responsibilities.
- Leadership Transition: Sabeen Mekan will transition to Chief Medical Officer effective February 1, 2026, responsible for clinical development and regulatory affairs, ensuring compliance and safety in drug development to enhance the company's market competitiveness.
- New Vice Presidents: Five new Vice Presidents appointed, underscoring the company's commitment to leadership development, which will enhance the team's expertise to better achieve strategic objectives and drive long-term growth.
See More
Zymeworks (ZYME) Reports Positive Phase 3 HERIZON-GEA-01 Results for Ziihera with Up to $440M in Milestone Payments
- Phase 3 Trial Results: Zymeworks presented positive results for Ziihera (zanidatamab-hrii) in the HERIZON-GEA-01 trial for HER2-positive gastroesophageal adenocarcinoma at ASCO GI, indicating strong potential as a first-line treatment.
- Milestone Revenue: The company stated that up to $440 million in milestone payments related to regulatory approvals of Ziihera in the U.S., Europe, Japan, and China could significantly enhance its financial position and market competitiveness.
- Cash Flow Outlook: As of December 31, 2025, Zymeworks holds approximately $270.6 million in cash, cash equivalents, and marketable securities, which, combined with anticipated regulatory milestone payments, is expected to provide cash runway beyond 2028.
- R&D Pipeline Progress: The company is conducting a global Phase 1 trial of ZW191 for solid tumors, with dose optimization underway, and further data from this study is expected to be presented at a major medical conference in 2026, bolstering its R&D capabilities.
See More
Zymeworks Reports Positive Phase 3 Results for Ziihera with Up to $440 Million in Potential Milestones
- Clinical Trial Success: Ziihera demonstrated significant improvement in progression-free survival in the HERIZON-GEA-01 Phase 3 trial for HER2-positive gastroesophageal adenocarcinoma, exceeding a four-month increase over the control group, which is expected to drive future regulatory approvals and market sales.
- Potential Revenue Growth: Zymeworks anticipates up to $440 million in regulatory milestone payments, with $250 million from the U.S. market, significantly enhancing the company's financial flexibility and long-term growth potential.
- Share Repurchase Program: The company announced a $125 million share repurchase plan in November 2025, having repurchased approximately $19 million worth of shares, aimed at enhancing shareholder value by reducing the share count while maintaining cash resources for operations and growth investments.
- Strong Financial Foundation: As of December 31, 2025, Zymeworks reported approximately $270.6 million in cash and cash equivalents, combined with anticipated regulatory milestone payments, expected to support operations beyond 2028, ensuring long-term sustainable growth.
See More
Zymeworks Reports Positive Phase 3 HERIZON-GEA-01 Results for Ziihera with Up to $440M in Milestone Payments
- Clinical Trial Success: Ziihera demonstrated significant improvement in progression-free survival in the HERIZON-GEA-01 Phase 3 trial for HER2-positive gastroesophageal adenocarcinoma, exceeding a four-month increase over the control group, which is expected to drive future regulatory approvals.
- Milestone Payment Potential: Zymeworks stands to earn up to $440 million in milestone payments from regulatory approvals of Ziihera, with $250 million potentially from the U.S. market, highlighting the company's strong growth potential in global markets.
- Share Repurchase Program: The company announced a $125 million share repurchase plan in November 2025, aimed at enhancing shareholder value by reducing share count while maintaining financial flexibility for future growth investments.
- Strong Financial Foundation: As of December 31, 2025, Zymeworks reported approximately $270.6 million in cash and cash equivalents, combined with anticipated milestone payments, expected to support operations beyond 2028, ensuring long-term financial stability.
See More
